Dimensional Fund Advisors LP Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Dimensional Fund Advisors LP increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 14.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 908,329 shares of the company’s stock after purchasing an additional 117,159 shares during the period. Dimensional Fund Advisors LP owned approximately 2.51% of iTeos Therapeutics worth $13,481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ITOS. Candriam S.C.A. purchased a new position in shares of iTeos Therapeutics during the 2nd quarter valued at about $7,558,000. Acadian Asset Management LLC purchased a new position in iTeos Therapeutics during the first quarter valued at approximately $3,337,000. Kennedy Capital Management LLC purchased a new position in iTeos Therapeutics during the first quarter valued at approximately $1,988,000. Los Angeles Capital Management LLC acquired a new position in iTeos Therapeutics in the first quarter valued at approximately $401,000. Finally, Victory Capital Management Inc. boosted its position in iTeos Therapeutics by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 110,389 shares of the company’s stock worth $1,638,000 after purchasing an additional 16,629 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Up 3.5 %

ITOS opened at $10.02 on Friday. The company has a market cap of $361.95 million, a price-to-earnings ratio of -2.65 and a beta of 1.36. The firm’s fifty day simple moving average is $14.62 and its two-hundred day simple moving average is $14.55. iTeos Therapeutics, Inc. has a 52-week low of $8.20 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.86. The firm had revenue of $35.00 million for the quarter, compared to analysts’ expectations of $4.20 million. On average, research analysts forecast that iTeos Therapeutics, Inc. will post -3.64 EPS for the current year.

Analysts Set New Price Targets

ITOS has been the subject of several analyst reports. Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 target price for the company. JPMorgan Chase & Co. decreased their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Wedbush restated an “outperform” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Monday, September 16th.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.